Tom Frohlich used a three-pronged test for his next role: deep conviction the science will benefit patients, a strong team he enjoys working with, and a place where his personal skills could make a significant impact. This structured approach ensures alignment between personal values, team dynamics, and company needs.
Jade's strategy involves acquiring assets from Paragon, a company renowned for its protein engineering and half-life extension technology. This allows Jade to start with high-quality, potentially best-in-class antibody candidates without building the specialized discovery infrastructure in-house, accelerating its path to the clinic with a competitive advantage.
Jade Biosciences grew from 0 to 70 employees virtually in under a year. To manage this, leadership intentionally defined core values like "advance what matters" through company-wide sessions. This proactive approach ensures alignment and a strong identity in a remote-first, high-growth environment, moving beyond just 'what' is done to 'how' it is done.
Jade's CEO Tom Frohlich initially aimed to be a PhD biochemist but discovered he wasn't skilled at bench science. Instead of abandoning his passion, he pivoted to the pharmaceutical industry's business side. This allowed him to leverage his love for science while excelling in a commercial environment, demonstrating a successful model for recalibrating a scientific career.
Jade's CEO Tom Frohlich draws inspiration from legendary drug hunter Dr. Paul Janssen. Janssen would motivate his teams by reminding them, "hurry up because the patients are out there and they're waiting." This frames the work not as a scientific or business exercise, but as a moral imperative, fostering a powerful sense of purpose and urgency.
Unlike typical safety-focused Phase 1 trials, Jade's trial for IgA nephropathy in healthy volunteers provides highly translatable efficacy data. Measuring the drop in IgA, a key biomarker, in healthy subjects directly predicts the drug's clinical activity in patients, significantly de-risking later-stage development before treating a single patient.